Our work provides a distinct and complementary contribution by addressing a broader set of five specific clinical aims, including tumor grading, molecular subtyping (e.g., IDH status), and distinguishing glioma from other entities Like PCNSL. This evidence concerns the gene IDH1 and central nervous system cancer.